NASDAQ:LYEL

Lyell Immunopharma Stock Insider Trading

Healthcare > Biotechnology

Buy LYEL

*Your capital is at risk

$12.57

-2.32 (-15.58%)

At Close: Jun 03, 2026

Lyell Immunopharma Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 93.60. In total, the insiders bought 4.74M and sold 39.63K LYEL shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	93.60
● Buy	4.74M shares
● Sell	39.63K shares
63% Buy Activity Moderate Negative Correlation
Buy Signal Medium Confidence Mar 06, 2026 Analysis Breakdown: Strongly supported by a very high Insider Power Score of 93.6. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jun 09, 2025 Buy	Common Stock J-Other	Shook David Insider	Other	0 Value: $0
Jun 09, 2025 Buy	Common Stock J-Other	Meltz Mark A Insider	Other	0 Value: $0
Jun 09, 2025 Buy	Common Stock J-Other	Bachleda Mark Insider	Other	0 Value: $0
Jun 09, 2025 Buy	Common Stock A-Award	Shook David Chief Medical Officer	Officer	21 900 Value: $273.1K
Jun 09, 2025 Buy	Option (right to buy) A-Award	Shook David Chief Medical Officer	Officer	43 750 Value: $545.6K
Jun 09, 2025 Buy	Option (right to buy) A-Award	Meltz Mark A General Counsel	Officer	100 000 Value: $1.25M
Jun 09, 2025 Buy	Option (right to buy) A-Award	Bachleda Mark Director	Director	13 000 Value: $162.1K
May 15, 2025 Buy	Option (right to buy) A-Award	Klausner Richard Director	Director	130 000 Value: $52.2K
May 15, 2025 Buy	Option (right to buy) A-Award	Rieflin William Jl Director	Director	130 000 Value: $52.2K
May 15, 2025 Buy	Option (right to buy) A-Award	Friedman Cathy Director	Director	130 000 Value: $52.2K
May 15, 2025 Buy	Option (right to buy) A-Award	Brawley Otis W Director	Director	130 000 Value: $52.2K
May 15, 2025 Buy	Option (right to buy) A-Award	Nabel Elizabeth G Director	Director	130 000 Value: $52.2K
May 15, 2025 Buy	Option (right to buy) A-Award	Ramachandra Sumant Director	Director	130 000 Value: $52.2K
May 15, 2025 Buy	Option (right to buy) A-Award	Ramachandra Sumant Director	Director	130 000 Value: $52.2K
May 15, 2025 Buy	Option (right to buy) A-Award	Nabel Elizabeth G Director	Director	130 000 Value: $52.2K
May 15, 2025 Buy	Option (right to buy) A-Award	Brawley Otis W Director	Director	130 000 Value: $52.2K
May 15, 2025 Buy	Option (right to buy) A-Award	Friedman Cathy Director	Director	130 000 Value: $52.2K
May 15, 2025 Buy	Option (right to buy) A-Award	Rieflin William Jl Director	Director	130 000 Value: $52.2K
May 15, 2025 Buy	Option (right to buy) A-Award	Klausner Richard Director	Director	130 000 Value: $52.2K
Mar 31, 2025 Buy	Common Stock P-Purchase	Brawley Otis W Director	Director	35 640 Value: $20.0K
Mar 31, 2025 Buy	Common Stock P-Purchase	Brawley Otis W Director	Director	35 640 Value: $20.0K
Mar 21, 2025 Buy	Common Stock P-Purchase	Ramachandra Sumant Director	Director	200 000 Value: $115.2K
Mar 21, 2025 Buy	Common Stock P-Purchase	Ramachandra Sumant Director	Director	200 000 Value: $115.2K
Mar 17, 2025 Buy	Common Stock P-Purchase	Newton Charles W. Chief Financial Officer	C-Suite Officer	200 000 Value: $111.6K
Mar 14, 2025 Buy	Common Stock P-Purchase	Seely Lynn President And CEO	CEO / President	175 000 Value: $106.2K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT LYELL IMMUNOPHARMA, INC.

Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate ...

Read Full Profile Here